Table of Contents
<< Previous Issue | Feb 2015 (Vol: 2015, Issue: 2) | Next Issue >> |
- Section: Licensing
-
Theravance Finds a Good Match for its Phase III-Ready Nebulised COPD Therapy in Mylan
- Section: Mergers & Acquisitions
-
Shire’s Bet on NPS Pharma Pays Off with Natpara® Approval
-
Pfizer’s US$17 B Buyout of Hospira Paves the Way for a Split